FDA Licenses Drug to Prevent Joint Damage in Children with Hemophilia A
The U.S. Food and Drug Administration today approved a new use for the blood product Kogenate FS to reduce the frequency of bleeding episodes and prevent joint damage in children with the most severe form of hemophilia.